Schedule 13G ownership disclosure

SAB Biotherapeutics, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 78397T202

Event date: 2025-09-29

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Vivo Opportunity Fund Holdings, L.P.

    Shares: 25,931,000.00 · Class: 9.99%

  • Vivo Opportunity, LLC

    Shares: 25,931,000.00 · Class: 9.99%

  • Vivo Opportunity Cayman Fund, L.P.

    Shares: 2,619,000.00 · Class: 9.99%

  • Vivo Opportunity Cayman, LLC

    Shares: 2,619,000.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-096128
Form type
SCHEDULE 13G
Filer
SAB Biotherapeutics, Inc.
CIK
CIK 1833214
Filed
Oct 03, 2025
Reporting period
Sep 29, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub